2019
DOI: 10.2169/internalmedicine.1263-18
|View full text |Cite
|
Sign up to set email alerts
|

Pulmonary <i>Mycobacterium abscessus</i> Infection with Reactive AA Amyloidosis: A Case Report and Brief Review of the Literature

Abstract: We herein report a case involving a 64-year-old Japanese woman with a pulmonary Mycobacterium abscessus infection complicated by reactive AA amyloidosis, which, to our knowledge, has not been reported to date. The patient underwent gastrointestinal endoscopy for diarrhea during the treatment of pulmonary M. abscessus infection and was diagnosed with AA amyloidosis according to the histopathological findings from the endoscopic specimen. She died four months later. The prognosis of AA amyloidosis associated wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 19 publications
0
1
0
Order By: Relevance
“…Recently, intrinsically multidrug resistant Mycobacteroides abscessus (formerly Mycobacterium abscessus) species have drawn great attention for the difficult-to-treat infections they cause among cystic fibrosis patients who appear particularly vulnerable to them [1,2]. Also, there are reports of deadly disseminated infections even among non-cystic fibrosis patients [3][4][5][6]. Therefore, innovative therapies are needed to supplement an inadequate supply of antimycobacterial agents in a context of increasing drug resistance.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, intrinsically multidrug resistant Mycobacteroides abscessus (formerly Mycobacterium abscessus) species have drawn great attention for the difficult-to-treat infections they cause among cystic fibrosis patients who appear particularly vulnerable to them [1,2]. Also, there are reports of deadly disseminated infections even among non-cystic fibrosis patients [3][4][5][6]. Therefore, innovative therapies are needed to supplement an inadequate supply of antimycobacterial agents in a context of increasing drug resistance.…”
Section: Introductionmentioning
confidence: 99%